We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TRIP11-PDGFRB fusion in a patient with a therapyrelated myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia.
- Authors
Hoon-Gu Kim; Ja-Hyun Jang; Eun-Ha Koh
- Abstract
Background: Therapy-related myeloid neoplasm after treatment for acute promyelocytic leukemia (APL) is a relatively infrequent but severe complication. Most therapy-related myeloid neoplasms after treatment for APL are classified as therapy-related myelodysplastic syndrome or therapyrelated acute myeloid leukemia. Translocation of 5q31-33, PDGFRB occur rarely in therapyrelated myeloid neoplasm and there has been two identified PDGFRB partner genes located at 14q32, TRIP11 and KIAA1509. Results: The TRIP11-PDGFRB fusion was identified in a patient with therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment of APL using conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular methods. Cytogenetic analysis of the bone marrow aspirate revealed 46, XY, t(5;14)(q33;q32) in all 20 analyzed cells. No other cytogenetic abnormalities were observed. Break-apart FISH analysis demonstrated that rearrangement of PDGFRB at 5q33 was positive in 460 of 500 cells analyzed, while the PML-RARA rearrangement remained undetectable by RT-PCR. Sequencing of RT-PCR products revealed fusion between exon 16 of TRIP11 and exon 11 of PDGFRB. However, the KIAA1509-PDGFRB fusion was not detected by RT-PCR. Conclusion: We firstly demonstrated that therapy-related myeloid neoplasm with TRIP11-PDGFRB fusion was identified after treatment of APL.
- Subjects
MYELOID leukemia genetics; TUMOR treatment; MYELODYSPLASTIC syndromes; CHROMOSOMAL translocation; CHROMOSOMAL rearrangement
- Publication
Molecular Cytogenetics (17558166), 2014, Vol 7, Issue 1, p256
- ISSN
1755-8166
- Publication type
Case Study
- DOI
10.1186/s13039-014-0103-6